GLP1 agonists set to become the best-selling drugs in 2024: GlobalData
Shift could reflect a changing demand away from oncology toward addressing metabolic disorders
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Opdivo
Pfizer and BioNTech’s COVID-19 vaccine Comirnaty tops the list of best-selling drugs
Ends the nine-year reign of AbbVie’s Humira as the world’s best-selling pharma product
Nektar stops clinical trials for key cancer drug
The trials that Nektar stopped included those involving a combination of its drug Bempegaldesleukin with Bristol Myers Squibb Co’s…
US FDA approves new Bristol Myers cancer immunotherapy
The company said it expects the treatment to eventually garner annual sales of more than $4 billion
US FDA approves expanded use of Bristol Myers cancer drug Opdivo
The approval was based on data from a late-stage study showing the drug along with chemotherapy improved event-free survival and…
Key unmet needs in HNSCC may be partly addressed by clinical development in next decade: GlobalData
The next decade may see the introduction of personalised therapy options in locally advanced HNSCC settings along with…
Bristol Myers Squibb get EC approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with…
Opdivo plus Yervoy-based combinations now indicated in the EU for three different advanced cancer types: non-small cell lung…
CHMP advises approval for Bristol Myers Squibb’s Opdivo plus Yervoy with chemo for metastatic NSCLC
The European Commission will now review the CHMP recommendation
Bristol Myers says Opdivo performs well in kidney, lung cancer trials
Opdivo is one of Bristol’s top-selling drugs, but sales of the drug have slowed in recent years as it has been eclipsed by Merck…
Japan drug price reforms risk hurting investment: Bristol-Myers CEO
The Japanese government made reforms in 2018 that change how its national health system pays for new and innovative drugs